Institut Bergonie — Sponsor Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

3 Recruiting

10 Completed trials

1 Countries active

29 Unique IMPs

100% Results reported

Phase II

Phase III: 1 Phase II: 11 Phase I/II: 1

Oversight events:

1 urgent safety measure across 1 trial

View oversight register →

100%

10 of 10 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

DOXORUBICIN HYDROCHLORIDE 3 ATEZOLIZUMAB 2 IFOSFAMIDE 2 NIVOLUMAB 2 PEMBROLIZUMAB 2 (3S,3'S,3A'S,10A'S)-6-CHLORO-3'-(3-CHLORO-2-FLUOROPHENYL)-1'-(CYCLOPROPYLMETHYL)-6'-METHYL-2-OXO-1,2,3',3A',10',10A'-HEXAHYDRO-1'H-SPIRO[INDOLE-3,2'-PYRROLO[2',3':4,5]PYRROLO[1,2-B]INDAZOLE]-7'-CARBOXYLIC ACID 1 BERZOSERTIB 1 BINTRAFUSP ALFA 1 CABOZANTINIB 1 CARBOPLATIN 1 CISPLATIN 1 DACARBAZINE 1

All trials

13 total

PEMBROCABOSARC : Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas Recruiting

2023-509496-16-00 Phase II 1 country CABOZANTINIB; PEMBROLIZUMAB
AGADIR : Atezolizumab combined with EIK10001 (BDB001) and Immunogenic Radiotherapy in Patients with Advanced Solid Tumors Recruiting

2023-509492-16-00 Phase II 1 country ATEZOLIZUMAB; RESIQUIMOD SULFATE
PHASE III TRIAL INVESTIGATING BENEFIT OF INTENSIFIED PERI-OPERATIVE CHEMOTHERAPY WITHIN HIGH-RISK CINSARC PATIENTS WITH RESECTABLE SOFT-TISS… Recruiting

2023-509489-39-00 Phase III 1 country DACARBAZINE; DOXORUBICIN HYDROCHLORIDE; IFOSFAMIDE
DARIUS : A randomized non-comparative phase II multicentric trial on short term DARolutamide (ODM-201) concomitant to radiation therapy for … Ended

2023-509494-23-00 Phase II 1 country DAROLUTAMIDE; TRIPTORELIN
TORNADO : RANDOMIZED PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY PLUS RETIFANLIMAB (INCMGA00012) IN PATIENTS WITH SELECTED RETROPERITONEAL SA… Ended

2023-509498-21-00 Phase II 1 country DOXORUBICIN HYDROCHLORIDE; IFOSFAMIDE; RETIFANLIMAB
TRUST : BINTRAFUSP ALFA AND DOXORUBICIN HYDROCHLORIDE IN TREATING PATIENTS WITH ADVANCED SARCOMA Ended

2023-509497-30-00 Phase II 1 country BINTRAFUSP ALFA; DOXORUBICIN HYDROCHLORIDE
REGOMUNE : A phase I/II study of Regorafenib plus Avelumab in solid tumors Ended

2023-509500-15-00 Phase I/II 1 country REGORAFENIB
EMPIRE : Targeting MDM2 and PD1 in tumors with tertiary lymphoid structures Ended

2023-506823-28-00 Phase II 1 country (3S,3'S,3A'S,10A'S)-6-CHLORO-3'-(3-CHLORO-2-FLUOROPHENYL)-1'-(CYCLOPROPYLMETHYL)…
Targeting ATR in soft-tissue sarcomas: a randomized phase II study Ended

2023-509499-41-00 Phase II 1 country BERZOSERTIB; GEMCITABINE HYDROCHLORIDE
Integrative analysis of the tumor microenvironment and optimization of the immunotherapy duration in non-small cell lung cancer patients. Ended

2023-509490-23-00 Phase II 1 country ATEZOLIZUMAB; CARBOPLATIN; CISPLATIN; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PEME…
CAIRE : COMBINING EPIGENETIC AND IMMUNE THERAPY TO BEAT CANCER Ended

2023-509501-72-00 Phase II 1 country DURVALUMAB
CONGRATS : COMBINATION OF NIVOLUMAB PLUS RELATLIMAB IN PATIENTS WITH ADVANCED OR METASTATIC SOFT-TISSUE SARCOMA: A PROOF-OF-CONCEPT RANDOMIZ… Ended

2023-509495-42-00 Phase II 1 country NIVOLUMAB; RELATLIMAB
A multicentric phase II trial evaluating volrusotmig in patients with mature tertiary lymphoid structures solid tumors. Expired

2023-503451-94-00 Phase II 1 country VOLRUSTOMIG

Showing 1–13 of 13 trials

← All sponsors A–Z